For the Inventor, By the Inventor

Enter assignee name

Alpharetta, GA, United States of America

Inhibitex, Inc.

USPTO Granted Patents = 16

% Expired Patents = 25.0

CIPO Patents = 2

EPO Patents = 5

Forward Citations = 262

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Joseph M Patti (13 out of 27 patents)

Jeff T Hutchins (9 out of 9 patents)

Magnus A Hook (7 out of 25 patents)

4. Andrea Hall (6 out of 6 patents)

5. Timothy James Foster (6 out of 24 patents)

6. Paul Domanski (4 out of 4 patents)

7. Pietro Speziale (3 out of 6 patents)

8. Yi Xu (3 out of 8 patents)

9. Maria G Bowden (3 out of 3 patents)

10. Pratiksha Patel (3 out of 3 patents)

11. John Vernachio (2 out of 4 patents)

12. Karolina Madela (2 out of 2 patents)

13. Fiona Roche (2 out of 2 patents)

14. Mark Pallen (2 out of 2 patents)

15. Jouko V Sillanpaa (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 9351989 - Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections (2016-05-31),

2. 9296795 - Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections (2016-03-29),

3. 8759318 - Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections (2014-06-24),

4. 8475798 - [object Object] (2013-07-02),

5. 8017133 - Multicomponent vaccines (2011-09-13),

6. 7968100 - [object Object] (2011-06-28),

7. 7850974 - Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby (2010-12-14),

8. 7666438 - Multicomponent vaccines (2010-02-23),

9. 7615616 - Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby (2009-11-10),

10. 7381793 - [object Object] (2008-06-03),

11. 7364738 - Monoclonal antibodies to the CLFA protein and method of use in treating infections (2008-04-29),

12. 7241592 - Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use (2007-07-10),

13. 7115264 - Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections (2006-10-03),

14. 7045131 - Staphylococcal immunotherapeutics via donor selection and donor stimulation (2006-05-16),

15. 6979446 - Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections (2005-12-27),

Company Overview

Inhibitex, Inc. is a biopharmaceutical company based in Alpharetta, Georgia, focused on the development of innovative therapies for infectious diseases. The company specializes in advancing treatments that target viral infections, particularly in the realm of hepatitis. Through its research efforts, Inhibitex aims to address significant unmet medical needs by leveraging its expertise in virology and drug development, contributing to the broader landscape of antiviral therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#41 in Alpharetta, GA

#377 in Georgia

#19,922 in US

#37,831 in the World

Alpharetta, GA, United States of America

Inhibitex, Inc.

Forward Citations = 262

35 inventors:

Joseph M Patti (13 out of 27 patents)

Jeff T Hutchins (9 out of 9 patents)

Magnus A Hook (7 out of 25 patents)

4. Andrea Hall (6 out of 6 patents)

5. Timothy James Foster (6 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Inhibitex, Inc.. Retrieved from https://idiyas.com/company/inhibitex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…